Pentoxifylline decreases soluble CD40 ligand concentration and CD40 gene expression in coronary artery disease patients

References

• Corrado, E., Rizzo, M., Coppola, G., Fattouch, K., Novo, G., Marturana, I., Ferrara, F., Novo, S. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 2010, 17, 1–11.
   PubMed Web of Science ®Google Scholar
• Patel, S., Celermajer, D.S., Bao, S. Atherosclerosis-underlying inflammatory mechanisms and clinical implications. Int J Biochem Cell Biol 2008, 40, 576–580.
   PubMed Web of Science ®Google Scholar
• Wibaut-Berlaimont, V., Randi, A.M., Mandryko, V., Lunnon, M.W., Haskard, D.O., Naoumova, R.P. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: In vivo regulation of hemostasis, inflammation and apoptosis. J Thromb Haemost 2005, 3, 677–685.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio, L.M., Martín-Ventura, J.L., de Teresa, E., Farsang, C., Gaw, A., Gensini, G., Leiter, L.A., Langer, A., Martineau, P., Egido, J.; ACTFAST investigators. Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: A substudy of ACTFAST. Kidney Int Suppl 2008, 74, S60–S63.
   Google Scholar
• Kinlay, S., Schwartz, G.G., Olsson, A.G., Rifai, N., Sasiela, W.J., Szarek, M., Ganz, P., Libby, P.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004, 110, 386–391.
   PubMed Web of Science ®Google Scholar
• Hu, W.L., Qiao, S.B., Qian, S.B., Li, J.J. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Cytokine 2007, 40, 201–206.
   PubMed Web of Science ®Google Scholar
• Serrano, C.V. Jr, Pesaro, A.E., de Lemos, J.A., Rached, F., Segre, C.A., Gomes, F., Ribeiro, A.F., Nicolau, J.C., Yoshida, V.M., Monteiro, H.P. Native LDL-cholesterol mediated monocyte adhesion molecule overexpression is blocked by simvastatin. Cardiovasc Drugs Ther 2009, 23, 215–220.
   PubMed Web of Science ®Google Scholar
• Gómez-Garre, D., Muñoz-Pacheco, P., González-Rubio, M.L., Aragoncillo, P., Granados, R., Fernández-Cruz, A. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009, 156, 1218–1227.
   PubMed Web of Science ®Google Scholar
• Schönbeck, U., Libby, P. CD40 signaling and plaque instability. Circ Res 2001, 89, 1092–1103.
   PubMed Web of Science ®Google Scholar
• Davì, G., Tuttolomondo, A., Santilli, F., Basili, S., Ferrante, E., Di Raimondo, D., Pinto, A., Licata, G. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb 2009, 16, 707–713.
   PubMed Web of Science ®Google Scholar
• Monaco, C., Andreakos, E., Kiriakidis, S., Mauri, C., Bicknell, C., Foxwell, B., Cheshire, N., Paleolog, E., Feldmann, M. Canonical pathway of nuclear factor κ B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 2004, 101, 5634–5639.
   PubMed Web of Science ®Google Scholar
• Fuchs, D., Piller, R., Linseisen, J., Daniel, H., Wenzel, U. The human peripheral blood mononuclear cell proteome responds to a dietary flaxseed-intervention and proteins identified suggest a protective effect in atherosclerosis. Proteomics 2007, 7, 3278–3288.
   PubMed Web of Science ®Google Scholar
• Fuchs, D., Vafeiadou, K., Hall, W.L., Daniel, H., Williams, C.M., Schroot, J.H., Wenzel, U. Proteomic biomarkers of peripheral blood mononuclear cells obtained from postmenopausal women undergoing an intervention with soy isoflavones. Am J Clin Nutr 2007, 86, 1369–1375.
   PubMed Web of Science ®Google Scholar
• Devaraj, S., Jialal, I. Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: Biomediator activity. Arch Pathol Lab Med 2008, 132, 1432–1435.
   PubMed Web of Science ®Google Scholar
• Zhang, M., Xu, Y.J., Mengi, S.A., Arneja, A.S., Dhalla, N.S. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol 2004, 9, 103–111.
   PubMedGoogle Scholar
• Vukanic, Z.S., Colic, M., Dimitrijevic, M. Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro. Int Immunopharmacol 2007, 7, 167–174.
   PubMed Web of Science ®Google Scholar
• Maiti, R., Agrawal, N.K., Dash, D., Pandey, B.L. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol 2007, 47, 118–124.
   PubMed Web of Science ®Google Scholar
• Fernandes, J.L., de Oliveira, R.T., Mamoni, R.L., Coelho, O.R., Nicolau, J.C., Blotta, M.H., Serrano, C.V.Jr..Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease–a randomized placebo-controlled study. Atherosclerosis 2008, 196, 434–442.
   PubMed Web of Science ®Google Scholar
• Prasad, K., Lee, P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007, 192, 313–322.
   PubMed Web of Science ®Google Scholar
• Zhang, M., Xu, Y.J., Saini, H.K., Turan, B., Liu, P.P., Dhalla, N.S. Pentoxifylline attenuates cardiac dysfunction and reduces TNF-α level in ischemic-reperfused heart. Am J Physiol Heart Circ Physiol 2005, 289, H832–H839.
   PubMed Web of Science ®Google Scholar
• Chen, Y.M., Tu, C.J., Hung, K.Y., Wu, K.D., Tsai, T.J., Hsieh, B.S. Inhibition by pentoxifylline of TNF-α-stimulated fractalkine production in vascular smooth muscle cells: Evidence for mediation by NF-κB down-regulation. Br J Pharmacol 2003, 138, 950–958.
   PubMed Web of Science ®Google Scholar
• Lutgens, E., Lievens, D., Beckers, L., Donners, M., Daemen, M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 2007, 17, 118–123.
   PubMed Web of Science ®Google Scholar
• Rizvi, M., Pathak, D., Freedman, J.E., Chakrabarti, S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 2008, 14, 530–538.
   PubMed Web of Science ®Google Scholar
• Santilli, F., Basili, S., Ferroni, P., Davì, G. CD40/CD40L system and vascular disease. Intern Emerg Med 2007, 2, 256–268.
   PubMed Web of Science ®Google Scholar
• Lutgens, E., Daemen, M.J. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002, 12, 27–32.
   PubMed Web of Science ®Google Scholar
• Fouad, H.H., Al-Dera, H., Bakhoum, S.W., Rashed, L.A., Sayed, R.H., Rateb, M.A., Haidara, M.A., Soskic, S., Isenovic, E.R. Levels of sCD40 ligand in chronic and acute coronary syndromes and its relation to angiographic extent of coronary arterial narrowing. Angiology 2010, 61, 567–573.
   PubMed Web of Science ®Google Scholar
• Danese, S., Sans, M., Scaldaferri, F., Sgambato, A., Rutella, S., Cittadini, A., Piqué, J.M., Panes, J., Katz, J.A., Gasbarrini, A., Fiocchi, C. TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: A novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J Immunol 2006, 176, 2617–2624.
   PubMed Web of Science ®Google Scholar
• Lu, L.F., Cook, W.J., Lin, L.L., Noelle, R.J. CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J Biol Chem 2003, 278, 45414–45418.
   Google Scholar
• Fotin-Mleczek, M., Henkler, F., Hausser, A., Glauner, H., Samel, D., Graness, A., Scheurich, P., Mauri, D., Wajant, H. Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-κB activation. J Biol Chem 2004, 279, 677–685.
   PubMed Web of Science ®Google Scholar
• Vircheva, S., Alexandrova, A., Georgieva, A., Mateeva, P., Zamfirova, R., Kubera, M., Kirkova, M. In vivo effects of pentoxifylline on enzyme and non-enzyme antioxidant levels in rat liver after carrageenan-induced paw inflammation. Cell Biochem Funct 2010, 28, 668–672.
   PubMed Web of Science ®Google Scholar
• Cominacini, L., Anselmi, M., Garbin, U., Fratta Pasini, A., Stranieri, C., Fusaro, M., Nava, C., Agostoni, P., Keta, D., Zardini, P., Sawamura, T., Lo Cascio, V. Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-κB activation in patients with unstable angina. J Am Coll Cardiol 2005, 46, 799–806.
   PubMed Web of Science ®Google Scholar